High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
about
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 raMyeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphomaConditioning regimens for hematopoietic cell transplantation: one size does not fit allA comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.Cancer radioimmunotherapy.Thyroid dysfunction from antineoplastic agents.Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.Therapeutic options in mantle cell lymphoma.Radioimmunotherapy-based conditioning regimens for stem cell transplantationMyeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.I-Tositumomab in lymphoma.Treatment of lymphoma with adoptively transferred T cells.Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and managementRole of hematopoietic stem cell transplant in the management of follicular lymphoma.Unresolved issues in diffuse large B-cell lymphomas.Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Transplantation for non-Hodgkin lymphoma.Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.Radioimmunotherapy in mantle cell lymphoma.The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL).Radioimmunotherapy for hematopoietic cell transplantation.A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.Advances and application of radioimmunotherapy in non-Hodgkin lymphoma.Should there be a standard therapy for mantle cell lymphoma?
P2860
Q30481608-4F864C57-23D7-4C58-A55B-479772EA639BQ33605275-A6949E59-C076-406C-A479-6C376EC4D801Q33915986-C8DDC7A7-DD00-4D1D-B1D9-037ACD752E25Q33917170-64DF0A8E-C85C-4FE3-80FC-365BDE7AD57BQ34089567-62F35E0E-1C97-4818-9198-1A65FA1E0D7BQ34255798-67F22712-6B29-45E6-A306-D024860547F7Q35070045-920C5E92-F0F7-45EF-95DA-987FB874EEFFQ35500038-3598F264-1B16-4117-A716-3F2DFD071CE4Q36301583-253B76F5-8727-4225-9F2F-800325C17B06Q36469671-733101BC-EACE-450E-882C-81179AD23DF3Q36474029-CD83C9CF-4474-4805-ABD7-20D02A49AB13Q36787584-504B870E-D959-42C8-8358-F2EBFA100016Q36842993-58A0C84F-6C3E-46AC-97DC-D603AF5BA17AQ36905562-8DCBA501-0C26-4BBF-B138-B40A4B2CF67DQ36950052-88F64148-2706-4716-96A1-22B9B4FF9789Q36964464-4D717319-5A55-4DCB-9EDC-B2C5BFC39CCEQ36987727-6CF39CC6-ADFD-49F6-A33E-8861B706F7FDQ37093669-EC3AF3FF-864A-41BB-A045-83B3DE832BD1Q37125119-DE58E0BD-697B-4BDC-8AE0-DABC31844EC9Q37132248-3E9714D3-9A9B-41CB-93CB-079F0D65E271Q37169112-82950776-7D2B-4A53-9DDF-4E150A0578E9Q37401659-76B10556-CCD8-4F97-BE22-2E3B0FD8A72BQ37419728-445CEBA3-3B6E-4350-863D-3710B4AB967CQ37519042-AC7932F4-B1A3-4504-8D61-CF3B691A4858Q37533977-6DD75A02-59A4-4411-963F-C054576C5B97Q37705417-F60A04D9-A7A5-45F7-9BC9-10A66558E1FEQ37752447-21ECF566-B43A-45F3-BC4B-140BC59508B3Q37810079-FD591B31-97A9-4022-9716-A8A4875BAD6CQ37810267-8ED98680-777E-44E8-A67B-A2238AFC878DQ37824456-F39FCE7C-38F2-441A-850F-665DD417EC90Q37854714-66791EE7-19BE-43B8-B9B5-6EA1DE69AE2AQ38017790-BD3F32DC-0DA9-4D7B-BBEC-095E2542EA46Q38074021-3072762A-9151-4C29-A2BA-6DAE03EA6896Q38096058-A52CE4B8-5979-4889-A96B-25D609D5EB7CQ38259725-788AB664-A9C5-4C1A-BCA1-20A9EC4C602BQ38473731-4474FF78-B83C-463F-8066-3AA181FBEF41Q38552083-BADD87F5-9D36-476E-8ADC-9CBF0EE56973Q39564060-B7055656-6861-4E4A-8932-DD53751F4F43Q39591787-CD45C25D-B2DB-4D82-B156-6219E5E845A6Q39779748-4C8DEA1D-B580-425B-817A-4309AF182177
P2860
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
High-dose [131I]tositumomab (a ...... or refractory B-cell lymphoma.
@en
High-dose [131I]tositumomab
@nl
type
label
High-dose [131I]tositumomab (a ...... or refractory B-cell lymphoma.
@en
High-dose [131I]tositumomab
@nl
prefLabel
High-dose [131I]tositumomab (a ...... or refractory B-cell lymphoma.
@en
High-dose [131I]tositumomab
@nl
P2093
P50
P356
P1476
High-dose [131I]tositumomab (a ...... or refractory B-cell lymphoma.
@en
P2093
Darrell R Fisher
Janet F Eary
John M Pagel
Joseph G Rajendran
Ted A Gooley
P304
P356
10.1200/JCO.2006.09.1215
P407
P577
2007-02-20T00:00:00Z